Perbedaan Brigit Biofarmaka Teknologi Tbk. dan Sumber Mineral Global Abadi Tbk.: Brigit Biofarmaka Teknologi Tbk. diperdagangkan di Rp254 (kapitalisasi pasar 172,82 M, volume 24 jam 592,2 rb), sedangkan Sumber Mineral Global Abadi Tbk. diperdagangkan di Rp76 (kapitalisasi pasar 638,75 M, volume 24 jam 21,58 jt). Perbedaan utamanya: Sumber Mineral Global Abadi Tbk. jauh lebih besar — sekitar 3,7× kapitalisasi pasar Brigit Biofarmaka Teknologi Tbk., dan Sumber Mineral Global Abadi Tbk. lebih aktif diperdagangkan (21,58 jt vs 592,2 rb). Mana yang lebih baik tergantung tujuan investasimu.
| OBAT | SMGA | |
|---|---|---|
Kapitalisasi Pasar | 172,82 M | 638,75 M |
Volume | 592,2 rb | 21,58 jt |
Lot | 5,92 rb | 215,82 rb |
Perputaran | 147,05 jt | 1,58 M |
Harga Rata-rata | 248,31 | 73,21 |
Nilai Transaksi | 147,05 jt | 1,58 M |
Harga Ekuilibrium Indikatif | 254 | 76 |
Volume Ekuilibrium Indikatif | 10 | 12,3 rb |
Imbal hasil berjalan pada periode standar
Berita terbaru kedua aset
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Selengkapnya di halaman OBAT →PT Sumber Mineral Global Abadi Tbk (the Company) was established based on Notarial Deed No. 2 dated October 19, 2016 of Selina Bertha Eny, S.H., a notary in South Tanggerang. The Company started its commercial operations in 2016. The Company’s immediate and ultimate parententities are PT Sumber Global Energy Tbk and PT Sumbermas Inti Energi, respectively, both entities domiciled in Jakarta. The controlling interest of the Company is PT Sumber Global Energy Tbk.
Selengkapnya di halaman SMGA →